Acute Coronary Syndrome
Purpose of Research
A Phase III, double-blind, randomized placebo-controlled study to evaluate the effects of Dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent acute coronary syndrome (ACS).
Patients who have recently been hospitalized for an Acute Coronary Syndrome (ACS) which is a myocardial infarction or ischemia. Patients who are selected as a possible participant in this study because they have a high risk of experiencing another cardiovascular event.